Last reviewed · How we verify
NCT05765032
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Phase 1, PHASE2 trial testing SHR-A1921； in Advanced Solid Tumor in 220 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2025
Quick facts
| Lead sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 220 |
| Start date | 30 December 2022 |
| Primary completion | 30 April 2025 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- SHR-A1921；
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of SHR-A1921 in combination with other anti-cancer agents in patients with advanced solid tumors
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Trop2-targeted therapies in solid tumors: advances and future directions.
Liu X, Ma L, Li J, Sun L, et al · · 2024 · cited 54× · PMID 38948057 · DOI 10.7150/thno.98178
Verify or expand the search:
- PubMed search for NCT05765032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other Suzhou Suncadia Biopharmaceuticals Co., Ltd. trials
Trials by the same sponsor.
- NCT06844474 — A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC · Phase 2 · recruiting
- NCT06703177 — A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT06643754 — A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
- NCT06618651 — A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06640257 — A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05765032 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Last refreshed: 26 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05765032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing